Working… Menu

Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00335101
Recruitment Status : Withdrawn (Sponsor Decision to withdraw study (comparative product withdrawn from the market))
First Posted : June 8, 2006
Last Update Posted : April 29, 2019
Information provided by (Responsible Party):
GE Healthcare

Brief Summary:
The study is to evaluate and compare the effects on kidney function of three iodinated contrast media (CM) in patients at risk of kidney damage evaluating serum creatinine (Scr) concentrations up to three days after CM administration.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease (CAD) Renal Impairment Diabetes Mellitus Drug: Iodixanol, Ioversol, Iopromide Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Diagnostic
Study Start Date : June 2006

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Primary endpoint:
  2. Maximum peak increase in SCr from baseline up to day 3.
  3. Secondary endpoints:
  4. Change in SCr from baseline to day 2 and to day 3
  5. Number of subjects with contrast-induced nephropathy (CIN)
  6. Quality of diagnostic information

Secondary Outcome Measures :
  1. Coronary Artery Disease (CAD)
  2. Renal Impairment
  3. Diabetes mellitus

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with a combination of DM (type I or II) and renal impairment (RI), defined as SCr ≥150 µmol/L (1.7 mg/dL) for men and ≥133 µmol/L (1.5 mg/dL) for women or creatinine clearance (CrCl) ≤50 mL/min calculated according to Cockroft-Gault formula, referred for coronary angiography with or without PCI.

Exclusion Criteria:

  • Concurrent administration of potentially nephroprotective or nephrotoxic drugs is not allowed. Subjects undergoing dialysis or kidney transplantation or with CrCl < 20 mL/min will not be included.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00335101

Layout table for location information
United States, New Jersey
GE Healthcare
Princeton, New Jersey, United States, 08540
GE Healthcare
Munich, Germany, 80807
Sponsors and Collaborators
GE Healthcare
Layout table for investigator information
Study Director: Marc Pignot, PhD GE Healthcare
Study Director: Johnny Gibbs, Jr., CCRA GE Healthcare
Layout table for additonal information
Responsible Party: GE Healthcare Identifier: NCT00335101    
Other Study ID Numbers: GE-012-091
First Posted: June 8, 2006    Key Record Dates
Last Update Posted: April 29, 2019
Last Verified: April 2019
Keywords provided by GE Healthcare:
Coronary Artery Disease (CAD), Renal Impairment, Serum creatinine (SCr), Iodixanol, Ioversol, Iopromide, Contrast Induced Nephropathy (CIN)
Additional relevant MeSH terms:
Layout table for MeSH terms
Renal Insufficiency
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Kidney Diseases
Urologic Diseases